Microdeletion Syndromes, Sex Chromosome Abnormalities, Trisomy 13, Trisomy 18, Trisomy 21
Conditions
Keywords
22q, DiGeorge, Angelman, Cri du chat, Miller Dieker, 1p36, Phelan McDermid, Prader Willi, Wolf Hirschorn, Smith Magenis, Trisomy 21, Down syndrome, Trisomy 18, Edwards syndrome, Trisomy 13, Patau syndrome, Monosomy X, Turner syndrome, XXY, Klinefelter syndrome, XXX, XYY
Brief summary
The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.
Detailed description
The primary purpose of this study is to collect family triads from families affected by a genetic or microdeletion/duplication (MD/D) syndrome to further develop non-invasive prenatal testing based on fetal DNA isolated from maternal blood. To assist with the development of the test, we will need to collect blood samples from women whose child was diagnosed with a genetic or MD/D syndrome, a blood sample from that child as well as a blood sample from their confirmed unaffected siblings. Since the test is based on Natera's Parental Support™ technology, buccal or blood samples from the biological fathers will also be requested. A recent abstract from a five year study on prenatal microarray testing revealed that 1.6% of women who present for routine prenatal indications have a positive microarray test. With the frequency of microdeletions and microduplications (MD/D) now known to be higher than previously thought, the field is likely to move toward offering invasive testing for microarray abnormalities to all pregnant women. Although non-invasive prenatal testing for aneuploidy is now clinically available, it has become clear that non-invasive prenatal testing for MD/D is equally important. However, access to these samples is made difficult as the standard of care for offering microarray analysis to all pregnant women will take time to come to fruition. We would like to develop this non-invasive as the standard of care so that less women will have to undergo invasive testing for the diagnosis of microarray abnormalities. Thus, there is an unmet need for the development of novel tests that would increase the scope of non-invasive prenatal screening.
Interventions
None listed
Sponsors
Natera, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Couples who have a child diagnosed with an autosomal chromosome abnormality (e.g. Down syndrome, Edwards syndrome, Patau syndrome). * Couples who have a child diagnosed with a sex chromosome abnormality (e.g. Turner syndrome, Klinefelter syndrome, Triple X syndrome, 47, XYY). * Couples who have a child diagnosed with a microdeletion/duplication syndrome (a positive microarray test).
Exclusion criteria
* Not an English language or Spanish language speaker * Genetics report is not available
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and Specificity of the test to diagnose chromosomal microdeletions and aneuploidy in a fetus | 4 years |
Countries
United States
Outcome results
None listed